Genmab A (GMAB) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Genmab A  (NASDAQ: GMAB)


Genmab A's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Genmab A's ROI in the fourth quarter of 2025?
Genmab A achieved a return on average invested assets (ROI) of 17.27 % in its fourth quarter of 2025, this is above GMAB's average return on investment of 15.76%.
Genmab As investments during the 12 months ending in the fourth quarter of 2025 are valued at $7 billion

ROI has improved compared to 7.49% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 128 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 922.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Investment Change TTM 42.92 % 55.42 % 50.2 % 58.06 % 44.84 %
Y / Y Net Income Change TTM 80.84 % -46.86 % -10.38 % 21.91 % 43.97 %
Investment (TTM) in Millions 7,872 7,872 6,464 7,872 6,583
Return On Investment (TTM) 17.27 % 7.49 % 11.37 % 10.9 % 13.65 %
GMAB's Overall Ranking # 922 # # # #
Seq. Investment Change TTM 4.48 % 11.44 % 5.24 % 16.65 % 13.62 %
Seq. Net Income Change TTM 141 % -26.58 % 9.78 % -6.9 % -29.18 %
Net Income (TTM) in Millions 1,299 539 734 669 718

GMAB Company Profile >> Back to GMAB Roi Comparisons >> See Annual GMAB Return On Investment



Return On Investment GMAB's Ranking
Within: No.
Industry # 54
Sector # 129
Overall # 922

Return On Investment Statistics
High Average Low
22.28 %
15.76 %
10.37 %
(Dec 31 2020)   (Dec 31 2025)







Financial Statements
Genmab A's IV. Quarter Investments $ 7,872 Millions GMAB's Balance sheet
Genmab A's IV. Quarter Income $ 963 Millions Quarterly GMAB's Income Statement
GMAB's Income by Division See GMAB's Income by Division


GMAB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 7,872 6,583 5,178 4,061 3,510
Y / Y Investment Growth 19.58 % 27.12 % 27.52 % 15.71 % 7.35 %
Net Income in Millions 963 1,133 631 772 470
Y / Y Net Income Growth -15 % 79.56 % -18.26 % 64.1 % -35.42 %
Annual Return On Investment 12.23 % 17.21 % 12.19 % 19.01 % 13.4 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 12.23 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GMAB's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GMAB's Competitors
Subscribers only: Roi for Genmab A's Suppliers
Subscribers only: Return On Investment for GMAB's Customers

Other Ratios
GMAB's Roa GMAB's Inventory Turnover Ratio GMAB's Growth Rates GMAB's Dividend Statistics
GMAB's Profitability Ratios GMAB's Asset Turnover Ratio GMAB's Dividend Growth
GMAB's Roe GMAB's Valuation Ratios GMAB's Financial Strength Ratios GMAB's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %
Puma Biotechnology Inc   25.39 %
Catalyst Pharmaceuticals Inc   24.25 %
Iradimed Corporation  22.97 %
Innoviva Inc   22.62 %
Illumina Inc   22.37 %

Date modified: 2026-07-07T11:25:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.